These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31784538)

  • 41. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
    Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
    Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
    Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence of a new auto-activating colony stimulating factor 3 receptor mutation (CSF3R-T595I) in acute myeloid leukemia and severe congenital neutropenia.
    Beekman R; Valkhof M; van Strien P; Valk PJ; Touw IP
    Haematologica; 2013 May; 98(5):e62-3. PubMed ID: 23508011
    [No Abstract]   [Full Text] [Related]  

  • 44. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.
    Wouters BJ; Löwenberg B; Erpelinck-Verschueren CA; van Putten WL; Valk PJ; Delwel R
    Blood; 2009 Mar; 113(13):3088-91. PubMed ID: 19171880
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CEBPA-regulated lncRNAs, new players in the study of acute myeloid leukemia.
    Hughes JM; Salvatori B; Giorgi FM; Bozzoni I; Fatica A
    J Hematol Oncol; 2014 Sep; 7():69. PubMed ID: 25252716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.
    van Vliet MH; Burgmer P; de Quartel L; Brand JP; de Best LC; Viëtor H; Löwenberg B; Valk PJ; van Beers EH
    Genet Test Mol Biomarkers; 2013 May; 17(5):395-400. PubMed ID: 23485358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
    Hickey CJ; Schwind S; Radomska HS; Dorrance AM; Santhanam R; Mishra A; Wu YZ; Alachkar H; Maharry K; Nicolet D; Mrózek K; Walker A; Eiring AM; Whitman SP; Becker H; Perrotti D; Wu LC; Zhao X; Fehniger TA; Vij R; Byrd JC; Blum W; Lee LJ; Caligiuri MA; Bloomfield CD; Garzon R; Marcucci G
    Blood; 2013 Jan; 121(1):159-69. PubMed ID: 23100311
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [CEBPA gene mutation analysis in acute myeloid leukemia].
    Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
    Bacher U; Schnittger S; Macijewski K; Grossmann V; Kohlmann A; Alpermann T; Kowarsch A; Nadarajah N; Kern W; Haferlach C; Haferlach T
    Blood; 2012 May; 119(20):4719-22. PubMed ID: 22442349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'.
    Hou HA; Lin LI; Chen CY; Tien HF
    Br J Cancer; 2009 Aug; 101(4):738-40. PubMed ID: 19623175
    [No Abstract]   [Full Text] [Related]  

  • 52. Enhancer and Transcription Factor Dynamics during Myeloid Differentiation Reveal an Early Differentiation Block in Cebpa null Progenitors.
    Pundhir S; Bratt Lauridsen FK; Schuster MB; Jakobsen JS; Ge Y; Schoof EM; Rapin N; Waage J; Hasemann MS; Porse BT
    Cell Rep; 2018 May; 23(9):2744-2757. PubMed ID: 29847803
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation.
    Avellino R; Havermans M; Erpelinck C; Sanders MA; Hoogenboezem R; van de Werken HJ; Rombouts E; van Lom K; van Strien PM; Gebhard C; Rehli M; Pimanda J; Beck D; Erkeland S; Kuiken T; de Looper H; Gröschel S; Touw I; Bindels E; Delwel R
    Blood; 2016 Jun; 127(24):2991-3003. PubMed ID: 26966090
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
    Sarojam S; Raveendran S; Vijay S; Sreedharan J; Narayanan G; Sreedharan H
    Asian Pac J Cancer Prev; 2015; 16(9):3785-92. PubMed ID: 25987038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis.
    Libura M; Pawełczyk M; Florek I; Matiakowska K; Jaźwiec B; Borg K; Solarska I; Zawada M; Czekalska S; Libura J; Salamanczuk Z; Jakóbczyk M; Mucha B; Duszeńko E; Soszyńska K; Karabin K; Piątkowska-Jakubas B; Całbecka M; Gajkowska-Kulig J; Gadomska G; Kiełbiński M; Ejduk A; Kata D; Grosicki S; Kyrcz-Krzemień S; Warzocha K; Kuliczkowski K; Skotnicki A; Jęrzejczak WW; Haus O
    Blood Cells Mol Dis; 2015 Dec; 55(4):284-92. PubMed ID: 26460249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.
    Wouters BJ; Jordà MA; Keeshan K; Louwers I; Erpelinck-Verschueren CA; Tielemans D; Langerak AW; He Y; Yashiro-Ohtani Y; Zhang P; Hetherington CJ; Verhaak RG; Valk PJ; Löwenberg B; Tenen DG; Pear WS; Delwel R
    Blood; 2007 Nov; 110(10):3706-14. PubMed ID: 17671232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia.
    Su L; Gao SJ; Li W; Tan YH; Cui JW; Hu RP
    Hematology; 2014 Sep; 19(6):324-8. PubMed ID: 24164801
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
    Fos J; Pabst T; Petkovic V; Ratschiller D; Mueller BU
    Blood; 2011 May; 117(18):4881-4. PubMed ID: 21389317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
    Fröhling S; Schlenk RF; Stolze I; Bihlmayr J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K
    J Clin Oncol; 2004 Feb; 22(4):624-33. PubMed ID: 14726504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.